US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

iShares Core High Dividend ETF

115.57

+1.130.99%

Post-market: 115.570.00000.00%19:26 EDT

Volume:431.45K

Turnover:49.80M

Market Cap:11.07B

PE:- -

High:115.83

Open:115.43

Low:114.78

Close:114.44

Loading ...

Overview Company News Filings

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

HEXAOM Strengthens Market Position with HDV Group Acquisition

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Hexaom SA Expands with HDV Group Acquisition

Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HDV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HDV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HDV\",,,,,undefined,":{"symbol":"HDV","market":"US","secType":"STK","nameCN":"iShares Core High Dividend ETF","latestPrice":115.57,"timestamp":1746216000000,"preClose":114.44,"halted":0,"volume":431453,"hourTrading":{"tag":"盘后","latestPrice":115.57,"preClose":115.57,"latestTime":"19:26 EDT","volume":55,"amount":6357.1,"timestamp":1746228363979},"delay":0,"floatShares":95750000,"shares":95750000,"eps":0,"marketStatus":"Market Closed","change":1.13,"latestTime":"05-02 16:00:00 EDT","open":115.43,"high":115.83,"low":114.78,"amount":49800730.02586,"amplitude":0.009175,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":114.44,"sharesOutstanding":95750000,"nav":114.436097,"aum":10957256287.75,"dividendRate":0.03526,"bidAskSpread":0.000306,"preHourTrading":{"tag":"盘前","latestPrice":114.44,"preClose":114.44,"latestTime":"08:47 EDT","volume":127,"amount":14533.88,"timestamp":1746190024560},"postHourTrading":{"tag":"盘后","latestPrice":115.57,"preClose":115.57,"latestTime":"19:26 EDT","volume":55,"amount":6357.1,"timestamp":1746228363979},"volumeRatio":1.4809468017292828,"impliedVol":0.1814,"impliedVolPercentile":0.924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HDV\",,,,,undefined,":{"symbol":"HDV","floatShares":95750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.4809468017292828,"shares":95750000,"dividePrice":4.075,"high":115.83,"amplitude":0.009175,"preClose":114.44,"low":114.78,"week52Low":106.005,"pbRate":"--","week52High":122.5,"institutionHeld":0,"latestPrice":115.57,"eps":0,"divideRate":0.03526,"volume":431453,"delay":0,"ttmEps":0,"open":115.43,"prevYearClose":112.26,"prevWeekClose":113.84,"prevMonthClose":115.1,"prevQuarterClose":121.12,"fiveDayClose":113.84,"twentyDayClose":118.41,"sixtyDayClose":115.32},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HDV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531544753","title":"Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2531544753","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531544753?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:30","pubTimestamp":1745929800,"startTime":"0","endTime":"0","summary":"– New findings to be presented at the 2025 European Association for the Study of the Liver  Congress continue to demonstrate the effectiveness of Livdelzi  in reducing pruritus in people with primary biliary cholangitis  –。– Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus  –。– Presentations in hepatitis B virus  and hepatitis C virus  will underscore Gilead’s commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting –。In hepatitis B , Gilead will present initial results from a Phase 1a study of a nov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-present-latest-advancements-across-123000497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","LU2106854487.HKD","LU1366192091.USD","BK4559","LU1989772840.SGD","HDV","IE00BKDWB100.SGD","IE00BYQQ9H92.USD","LU1430594728.SGD","LU1989772923.USD","LU2361045086.USD","PRT","LU0109394709.USD","LU2250418816.HKD","PBC","IE0005OL40V9.USD","BK4581","IE00BQXX3D17.EUR","LU1670627923.USD","IE0004086264.USD","LU0820561818.USD","BK4534","BK4533","LU0056508442.USD","LU0011850046.USD","LU1989764664.SGD","LU1989764748.USD","TDF","IE00B7SZLL34.SGD","LU0708995401.HKD","LU0198837287.USD","IE00B19Z3581.USD","LU2317271919.USD","LU2552382132.HKD","LU2361044949.HKD","BK4213","EC","LU0053666078.USD","EEA","LU2087625088.SGD","LU0107464264.USD","LU0557290698.USD","MA","LU0417517546.SGD","LU2420271590.USD","IE00BFSS8Q28.SGD","IE00B775H168.HKD","LU0494093205.USD","LU2054465674.USD","GILD"],"gpt_icon":0},{"id":"2526385370","title":"Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2526385370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526385370?lang=en_us&edition=fundamental","pubTime":"2025-04-09 14:00","pubTimestamp":1744178400,"startTime":"0","endTime":"0","summary":"– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058117/16259/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Long-Acting-Herpes-Simplex-Virus-Candidate-ABI-5366-and-Genital-Herpes-Prevalence-and-Treatment-Patterns-at-the-2025-ESCMID-Cong.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HDV","BK4139","BK4218","BK4585","BK4181","PK","BK4588","ASMB"],"gpt_icon":0},{"id":"2521496941","title":"Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496941?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline --. -- Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes --. SOUTH SAN FRANCISCO, Calif., March 20, 2025  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights.\"We are well-positioned to deliver important clinical data on four of our novel antiviral candidates in 2025, including proof-of-concept efficacy data expected this fall from the Phase 1b studies of ABI-5366 and ABI-1179 for recurrent genital herpes,\" said Jason Okazaki, chief executive officer and president of Assembly Bio. \"We anticipate that the rapid progress across our clinical ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","HDV","PK","BK4181","BK4218","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2519836627","title":"Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2519836627","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519836627?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:05","pubTimestamp":1741867500,"startTime":"0","endTime":"0","summary":"First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment. Rapid study start indicative of significant unmet need for chronic hepatitis delta treatment. SAN FRANCISCO, March 13, 2025----Vir Biotechnology, Inc.  today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta . ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submission to multiple regulatory agencies. ECLIPSE 3, a Phase 2b trial, is designed to provide important supportive data to help enable access and reimbursement strategies in key European markets.The significant unmet need in CHD and the potential for tobevibart and elebsir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-enrolls-first-patient-120500531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHD","VIR","LU1430594728.SGD","BK4139","BK4568","BK4588","LU1585245621.USD","BK4535","HDV","BK4504","BK4018","BK4585"],"gpt_icon":0},{"id":"2514837055","title":"Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837055","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837055?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032858/16259/en/Assembly-Biosciences-Doses-First-Participant-in-Phase-1a-Clinical-Study-of-Oral-Entry-Inhibitor-Candidate-ABI-6250-for-Hepatitis-Delta-Virus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","PK","BK4218","BK4585","BK4139","BK4181","HDV","BK4588"],"gpt_icon":0},{"id":"2507655189","title":"HEXAOM Strengthens Market Position with HDV Group Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2507655189","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507655189?lang=en_us&edition=fundamental","pubTime":"2025-01-30 01:06","pubTimestamp":1738170360,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Hexaom SA ( ($FR:ALHEX) ). HEXAOM has acquired 75.5% of the HDV Group, a company with extensive experience in h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hexaom-strengthens-market-position-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hexaom-strengthens-market-position-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV","BK4585","BK4588"],"gpt_icon":0},{"id":"2494585774","title":"Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2494585774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494585774?lang=en_us&edition=fundamental","pubTime":"2024-12-26 21:00","pubTimestamp":1735218000,"startTime":"0","endTime":"0","summary":"– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –  – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/26/3001938/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1b-Results-from-Clinical-Trial-Evaluating-Next-Generation-Capsid-Assembly-Modulator-Candidate-ABI-4334-in-Chronic-Hepatitis-B.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4585","BK4599","HDV","ALT","BK4588","ASMB","BK4181","BK4218","BK4139","LU1878469433.USD"],"gpt_icon":0},{"id":"2493743774","title":"Hexaom SA Expands with HDV Group Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2493743774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493743774?lang=en_us&edition=fundamental","pubTime":"2024-12-24 16:02","pubTimestamp":1735027339,"startTime":"0","endTime":"0","summary":"Hexaom SA (FR:ALHEX) has released an update. Hexaom SA has signed an agreement to acquire a 75.5% stake in the HDV Group, a house builder based in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hexaom-sa-expands-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hexaom-sa-expands-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HDV","BK4588"],"gpt_icon":0},{"id":"2492127968","title":"Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127968?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs. --Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026--. Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus  and hepatitis B virus . Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.Since the collaboration with Gilead was announced in October 2023, Assembly Bio has initiated clinical studies for four small molecule antiviral candidates. In mid-2024, a Phase 1a/b study for ABI-5366, a long-acting helicase-primase inhibitor for treatment of recurrent genital herpes a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HDV","BK4588","BK4215","ASMB","BK4139","EQR"],"gpt_icon":0},{"id":"2491354421","title":"Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2491354421","media":"Business Wire","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491354421?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":"– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs –。SAN FRANCISCO, December 12, 2024----Vir Biotechnology, Inc.  today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration  Breakthrough Therapy designation and European Medicines Agency  Priority Medicines  designation for the treatment of chronic hepatitis delta . The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AASLD The Liver Meeting in San Diego, U.S. Vir Biotechnology’s Phase 3 ECLIPSE registrational program evaluating tobevibart and elebsiran in CHD will commence in the first half of 2025.SOLSTICE is a Phase 2 study to evaluate the safety, tolerability, and efficacy of tobevibart,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-fda-breakthrough-210500608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4504","VIR","BK4018","BK4568","BK4079","LU1878469433.USD","BK4599","HDV","CHD","BK4535","COMP","BK4539","BK4139","ALT","BK4585"],"gpt_icon":0},{"id":"2484956973","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956973","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956973?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982500,"startTime":"0","endTime":"0","summary":"– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –。– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –。– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –。– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –。These data were presented in an oral session at the American Association for the Study of Liver Diseases  The Liver Meeting, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.Primary Endpoint Analysis from the Phase 2 SOLSTICE Tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-presents-positive-chronic-021500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHD","VIR","BK4139","BK4568","BK4588","BK4079","BK4535","ALT","LU1878469433.USD","HDV","RNA","BK4505","BK4539","COMP","BK4504","BK4018","BK4585"],"gpt_icon":0},{"id":"2484987837","title":"Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987837","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987837?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need –。– Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting –。SAN FRANCISCO, November 18, 2024----Vir Biotechnology, Inc.  today announced that the European Medicines Agency  Committee for Orphan Medicinal Products , has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta . This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET.In June 2024, the U.S. Food and Drug Adm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-positive-opinion-210500380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4504","COMP","HDV","MDCO","ALT","BK4568","VIR","BK4139","BK4585","BK4535","BK4079","LU1878469433.USD","BK4018","CHD","BK4588"],"gpt_icon":0},{"id":"2481316725","title":"Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481316725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481316725?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing. First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025. Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV with interim data expected by end of year. ABI-1179 and ABI-6250 candidates on track to enter clinic by end of year. “I’m thrilled with the continued execution against our ambitious goal of advancing four candidates targeting serious viral diseases in the clinic and releasing two interim data sets by year end,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “We recently reported positive interim Phase 1a data for ABI-5366 that exceeded our expectations and supporte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/assembly-biosciences-reports-third-quarter-210500996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","ASMB","BK4588","HDV"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HDV\",params:#limit:5,,,undefined,":[{"date":"2025-03-18","symbol":"HDV","amount":0.795075,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-18","defaultRemindTime":1742304600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-18","currency":"USD","dateTimestamp":1742270400000,"payDate":"2025-03-21"},{"date":"2024-12-17","symbol":"HDV","amount":1.12172,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-09-25","symbol":"HDV","amount":1.2295,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-11","symbol":"HDV","amount":0.92835,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2024-03-21","symbol":"HDV","amount":0.83549,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-22","defaultRemindTime":1711027800000,"name":"iShares High Dividend Equity Fun","recordDate":"2024-03-27","payableDate":"2024-03-22","currency":"USD","dateTimestamp":1710993600000,"payDate":"2024-03-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HDV\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-24","recordDate":"2015-06-26","paymentDate":"2015-06-30","value":0.724784,"currency":"USD"},{"executeDate":"2015-09-25","recordDate":"2015-09-29","paymentDate":"2015-10-01","value":0.722168,"currency":"USD"},{"executeDate":"2015-12-24","recordDate":"2015-12-29","paymentDate":"2015-12-31","value":0.715673,"currency":"USD"},{"executeDate":"2016-03-23","recordDate":"2016-03-28","paymentDate":"2016-03-30","value":0.676805,"currency":"USD"},{"executeDate":"2016-06-21","recordDate":"2016-06-23","paymentDate":"2016-06-27","value":0.679421,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HDV\",market:\"US\",delay:false,,,undefined,":{}}}